Literature DB >> 26971636

Combined biomarkers discriminate a low likelihood of bacterial infection among surgical intensive care unit patients with suspected sepsis.

Brendan J Kelly1, Ebbing Lautenbach2, Irving Nachamkin3, Susan E Coffin4, Jeffrey S Gerber5, Barry D Fuchs6, Charles Garrigan3, Xiaoyan Han7, Warren B Bilker8, Jacqueleen Wise9, Pam Tolomeo9, Jennifer H Han10.   

Abstract

Among surgical intensive care unit (SICU) patients, it is difficult to distinguish bacterial sepsis from other causes of systemic inflammatory response syndrome (SIRS). Biomarkers have proven useful to identify the presence of bacterial infection. We enrolled a prospective cohort of 69 SICU patients with suspected sepsis and assayed the concentrations of 9 biomarkers (α-2 macroglobulin [A2M], C-reactive protein, ferritin, fibrinogen, haptoglobin, procalcitonin [PCT], serum amyloid A, serum amyloid P, and tissue plasminogen activator) at baseline, 24, 48, and 72hours. Forty-two patients (61%) had bacterial sepsis by chart review. A2M concentrations were significantly lower, and PCT concentrations were significantly higher in subjects with bacterial sepsis at 3 of 4 time points. Using optimal cutoff values, the combination of baseline A2M and 72-hour PCT achieved a negative predictive value of 75% (95% confidence interval, 54-96%). The combination of A2M and PCT discriminated bacterial sepsis from other SIRS among SICU patients with suspected sepsis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-2-macroglobulin; Biomarker; Procalcitonin; Sepsis; Surgical intensive care unit; Systemic inflammatory response syndrome

Mesh:

Substances:

Year:  2016        PMID: 26971636      PMCID: PMC4841711          DOI: 10.1016/j.diagmicrobio.2016.01.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  63 in total

1.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

2.  Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections.

Authors:  Philipp Schuetz; Matthias Briel; Beat Mueller
Journal:  JAMA       Date:  2013-02-20       Impact factor: 56.272

3.  EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units.

Authors:  C Brun-Buisson; P Meshaka; P Pinton; B Vallet
Journal:  Intensive Care Med       Date:  2004-03-02       Impact factor: 17.440

4.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

Authors:  Philipp Schuetz; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Marcel Wolbers; Isabelle Widmer; Stefanie Neidert; Thomas Fricker; Claudine Blum; Ursula Schild; Katharina Regez; Ronald Schoenenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Mueller
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

5.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship.

Authors:  Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

6.  Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.

Authors:  David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal
Journal:  Crit Care Med       Date:  2010-04       Impact factor: 7.598

7.  Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.

Authors:  Djillali Annane; Alain Cariou; Virginie Maxime; Elie Azoulay; Gilles D'honneur; Jean François Timsit; Yves Cohen; Michel Wolf; Muriel Fartoukh; Christophe Adrie; Charles Santré; Pierre Edouard Bollaert; Armelle Mathonet; Roland Amathieu; Alexis Tabah; Christophe Clec'h; Julien Mayaux; Julie Lejeune; Sylvie Chevret
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

8.  Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit.

Authors:  Canan BalcI; Hülya Sungurtekin; Ercan Gürses; Ugur Sungurtekin; Bünyamin Kaptanoglu
Journal:  Crit Care       Date:  2002-10-30       Impact factor: 9.097

9.  Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

10.  Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis.

Authors:  Philipp Schuetz; Matthias Briel; Mirjam Christ-Crain; Daiana Stolz; Lila Bouadma; Michel Wolff; Charles-Edouard Luyt; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Long Wei; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Michael Tamm; Neera Bhatnagar; Heiner C Bucher; Beat Mueller
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

View more
  8 in total

1.  Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.

Authors:  Brendan J Kelly; Ebbing Lautenbach; Irving Nachamkin; Susan E Coffin; Jeffrey S Gerber; Barry D Fuchs; Charles Garrigan; Xiaoyan Han; Warren B Bilker; Jacqueleen Wise; Pam Tolomeo; Jennifer H Han
Journal:  Crit Care Med       Date:  2018-07       Impact factor: 7.598

Review 2.  Diagnosing sepsis - The role of laboratory medicine.

Authors:  Shu-Ling Fan; Nancy S Miller; John Lee; Daniel G Remick
Journal:  Clin Chim Acta       Date:  2016-07-04       Impact factor: 3.786

3.  Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis.

Authors:  Hanah Kim; Mina Hur; Hee-Won Moon; Yeo-Min Yun; Salvatore Di Somma
Journal:  Ann Intensive Care       Date:  2017-03-07       Impact factor: 6.925

Review 4.  Biomarkers of sepsis: time for a reappraisal.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Max Bisdorff; John C Marshall; Jean-Louis Vincent
Journal:  Crit Care       Date:  2020-06-05       Impact factor: 9.097

5.  Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study.

Authors:  Eric Gluck; H Bryant Nguyen; Kishore Yalamanchili; Margaret McCusker; Jaya Madala; Frank A Corvino; Xuelian Zhu; Robert Balk
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

6.  Differential protein expression in patients with urosepsis.

Authors:  Xu-Kai Yang; Nan Wang; Cheng Yang; Yang-Min Wang; Tuan-Jie Che
Journal:  Chin J Traumatol       Date:  2018-10-02

Review 7.  A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine.

Authors:  Anna Maria Azzini; Romolo Marco Dorizzi; Piersandro Sette; Marta Vecchi; Ilaria Coledan; Elda Righi; Evelina Tacconelli
Journal:  Ann Transl Med       Date:  2020-05

8.  A Minimal Parameter Set Facilitating Early Decision-making in the Diagnosis of Hemophagocytic Lymphohistiocytosis.

Authors:  Bas M Smits; Joris van Montfrans; Samuel A Merrill; Lisette van de Corput; Mariëlle van Gijn; Andrica de Vries; Cor van den Bos; Floor Abbink; Renate G van der Molen; Natasja Dors; Caroline Lindemans; Jaap J Boelens; Stefan Nierkens
Journal:  J Clin Immunol       Date:  2021-03-29       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.